https://www.selleckchem.com/products/thz1.html
The prevalence of stroke (either hemorrhagic or ischemic) was 11% (95% CI 3% to 23%), with notable heterogeneity (I² = 63.35%). Based on currently available literature, it is not possible to draw definite conclusions on the usefulness of ECMO for high-risk PE. Prospective, multicenter, large-scale studies or nationwide registries are needed to best define the role of ECMO for high-risk PE. PROSPERO registration ID CRD42019136282. To compare the potential beneficial effects of the angiotensin converting enzyme inhibitor (ACEI) benazepril an
Like
Comment
Share
